Histological section of a ciliary body. Credit: University of Bristol
A new study led by the University of Bristol has shown a common eye condition, glaucoma, could be successfully treated with a single injection using gene therapy, which would improve treatment options, effectiveness and quality of life for many patients.
Glaucoma affects over 64 million people worldwide and is a leading cause of irreversible blindness. It is usually caused by fluid building up in the front part of the eye, which increases pressure inside the eye and progressively damages the nerves responsible for sight. Current treatments include either eye drops, laser or surgery, all of which have limitations and disadvantages.
The research team led by academics at the Bristol Medical School: Translational Health Sciences tested a new approach that could provide additional treatment options and benefits. Their findings are published in the journal Molecular Therapy.
The researchers designed a gene therapy and demonstrated proof of concept using experimental mouse models of glaucoma and human donor tissue.
The treatment targeted part of the eye called the ciliary body, which produces the fluid that maintains pressure within the eye. Using the latest gene editing technology called CRISPR, a gene called Aquaporin 1 in the ciliary body was inactivated leading to reduced eye pressure.
Dr Colin Chu, Visiting Senior Research Fellow in the Bristol Medical School: Translational Health Sciences and corresponding author, said: “Currently there is no cure for glaucoma, which can lead to loss of vision if the disease is not diagnosed and treated early.
“We hope to advance towards clinical trials for this new treatment in the near future. If it’s successful it could allow a long-term treatment of glaucoma with a single eye injection, which would improve the quality of life for many patients whilst saving the NHS time and money.”
The academics are currently in discussion with industry partners to support further laboratory work and rapidly progress this new treatment option towards clinical trials.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Glaucoma
- Aerie Pharmaceuticals to Participate in Upcoming Virtual Investor Conferenceson February 22, 2021 at 9:30 am
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first- ...
- Hospital calls for proactive screening for glaucomaon February 21, 2021 at 12:27 pm
The study, done by doctors from Aravind Eye Hospital in Puducherry, assessed the treatment-seeking pattern among the south Indian population which comes to the hospital. Since people do not notice ...
- Nasal displacement of retinal vessels on the optic disc in glaucoma associated with a nasally angled passage through lamina cribrosaon February 18, 2021 at 1:33 pm
To investigate nasal displacement of (CRV) on the optic nerve head (ONH) in glaucoma in association with its passage through lamina cribrosa (LC). This cros ...
- Minimally Invasive Glaucoma Surgery (MIGS) Devices Market to reach $912 Million by 2023on February 16, 2021 at 8:12 pm
According to a new report published by Allied Market Research, titled, Minimally Invasive Glaucoma Surgery (MIGS) Devices Market by Surgery, Target, Product, and End User: Global Opportunity Analysis ...
- Glaucoma Eye Drops Market to Witness Huge Growth by 2026 | Novartis, Pfizer, Inotek Pharmaceutical, Mylanon February 16, 2021 at 1:41 pm
Stay up-to-date and exploit latest trends of Glaucoma Eye Drops Market with latest edition released by AMA. Glaucoma is caused by a build-up of fluid in the eye called aqueous humor, or simply aqueous ...
Go deeper with Google Headlines on:
Glaucoma
Go deeper with Bing News on:
Glaucoma gene therapy
- Advancing gene therapy for new glaucoma treatmentson February 22, 2021 at 4:44 am
When a patient is diagnosed with glaucoma, their treatment will focus on slowing down or stopping the disease to prevent vision loss. Glaucoma ...
- Challenges in Neuroprotective Nanomedicine Development: Progress Towards Noninvasive Gene Therapy of Glaucomaon February 17, 2021 at 4:00 pm
Gene therapy for glaucoma is a treatment that aims to stop and reverse vision loss in glaucoma patients by promoting cellular mechanisms associated with RGC protection and suppressing those ...
- Challenges in Neuroprotective Nanomedicine Development: Progress Towards Noninvasive Gene Therapy of Glaucomaon February 17, 2021 at 4:00 pm
It may not be likely that a cure for glaucoma is achievable within the next decade; however, it is highly possible that gene therapy will be clinically used to control glaucomatous vision loss in ...
- Neurophth Closes RMB 400 Million Series B Financingon February 9, 2021 at 7:03 am
We look forward to working alongside the Neurophth team to bring high-quality, worldwide competitive, significant gene therapy products to doctors and patients, globally." "In the past year ...
- Neurophth Closes RMB 400 Million Series B Financingon February 9, 2021 at 5:44 am
Neurophth Biotechnology Ltd., a fully-integrated genetic medicines company developing AAV-delivered gene therapies for the treatment of ...